StockData
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. (BCAX) stock

BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$9.60−0.15 (-1.54%)

Close on Nov 17, 2026Market cap $635.26MP/E –Yield –

Bicara Therapeutics EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

For fiscal 2025 it was -$2.52.

Annual eps

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.52–
FY2024Dec 31, 2024-$4.05–
FY2023Dec 31, 2023-$89.61–

Quarterly eps

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$1.04–
Q2 FY2026Jun 30, 2026-$0.82–
Q1 FY2026Mar 31, 2026-$0.93–
Q3 FY2025Sep 30, 2025-$0.67–
Q2 FY2025Jun 30, 2025-$0.50–
Q1 FY2025Mar 31, 2025-$0.68–
Q3 FY2024Sep 30, 2024-$1.60–
Q2 FY2024Jun 30, 2024-$19.01–
Q1 FY2024Mar 31, 2024-$18.94–
Q3 FY2023Sep 30, 2023-$38.23–

More Bicara Therapeutics figures

See a number that looks wrong?